Skip to content

Comparison of 0.375% Ropivacaine and 0.25% Levobupivacaine for Infraclavicular Brachial Plexus Block

0.25% Levobupivacaine Versus 0.375% Ropivacaine: a Comparative Study in Ultrasound-Guided Infraclavicular Brachial Plexus Block

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03679897
Enrollment
46
Registered
2018-09-21
Start date
2018-09-18
Completion date
2018-12-08
Last updated
2018-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Regional Anesthesia

Brief summary

Infraclavicular brachial plexus block has been used more frequently with the development of high-resolution ultrasound. Compared with peripheral nerve block using landmark technique or nerve stimulator technique, ultrasound-guided peripheral nerve block decreases the required dose of local anesthetics. As the dose of the drug used decreases, the systemic toxic effects of local anesthetics are reduced. However, the decreased dose of the drugs might have influence on the onset time of local anesthetics. Thus, the investigator aimed to evaluated the onset time of the two equipotent local anesthetics, 0.375% ropivacaine and 0.25% levobupivacaine.

Interventions

ultrasound-guided infraclavicular brachial plexus block with 0.375% ropivacaine solution

ultrasound-guided infraclavicular brachial plexus block with 0.25% levobupivacaine solution

Sponsors

Asan Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* American Society of Anesthesiologists physical status 1-3 * Patients undergoing upper extremity surgery with infraclavicular brachial plexus block

Exclusion criteria

* Patients who do not agree to participate in clinical trial * Patients presenting with neurological deficits of the upper arm, severe coagulopathy, chronic renal failure, cardiopulmonary compromise, cerebral vascular disease, hypersensitivity to hyaluronidase or local anesthetics or local infection at the site of the infraclavicular block, pregnancy

Design outcomes

Primary

MeasureTime frameDescription
onset time of sensory blockup to 40 minutessensory block of 4 nerves(radial, median, ulnar, musculocutaneous nerve) was assessed with pin-prick test every 5 minutes till 40 minutes from the completion of drug injection

Secondary

MeasureTime frameDescription
onset time of motor blockup to 40 minutesmotor block of 4 nerves(radial, median, ulnar, musculocutaneous nerve) was assessed with movement of fingers and elbow every 5 minutes till 40 minutes from the completion of drug injection
duration of analgesia24 hoursdefined as time for first request by the patient

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 23, 2026